DAVA Oncology retweeted
"Fantastic talk by @BrendanGuercio at #DAVAGU on the gut microbiome and IO outcomes in RCC!" — @SaadAtiq24
483 slides, 94 trials: @DrsartorOliver (PSMAddition), @EJonasch (HIF-2α), @katy_beckermann (LITESPARK-011)
Thanks @DAVAOnc for sharing the data!
hubs.ly/Q04DQ9BK0
DAVA Oncology retweeted
Thankful to the @DAVAOnc team for the opportunity to discuss the recent phase I data on @biohaven FGFR ADC, and on transdermal estradiol for treating prostate cancer. #DAVAGU #Bermuda
Dr. @DavidBenjaminMD (@HoagHealth) presented BHV-1530, an anti-FGFR3 ADC with a topoisomerase I inhibitor payload. Phase 1 (n=17, 1.0-7.0 mg/kg): confirmed responses in 3 (17.6%; 2 UC, 1 HNSCC), tumor reduction 47.1%, DCR 64.7%. Most common TEAE: nausea 41.2%. #DAVAGU
DAVA Oncology retweeted
Setting the Stage for DAVA’s Peer Summit on Head and Neck Cancer @DAVAOnc #DAVAHEADANDNECK
DAVA Oncology retweeted
Salivary, ACC and thyroid cancers @DAVAOnc #DAVAHEADANDNECK
DAVA Oncology retweeted
Thanks to Dr. Vinay Jain & @DAVAOnc for an outstanding inaugural peer forum at The Broadmoor!
After decades of negative trials, KEYNOTE-689 has transformed care, while 3 promising EGFR-targeting bispecifics are reshaping the R/M landscape.
Honored to shared our work @providence
DAVA Oncology retweeted
Final panel on supportive care in HNSCC @DAVAOnc #DAVAHEADANDNECK
DAVA Oncology retweeted
Strategies to enhance activity of checkpoint inhibitors in HNSCC @DAVAOnc #Davaheadandneck
What an inspiring few days at the DAVA Peer Forum on Head & Neck Cancer! 🙏
Our sincere thanks to the faculty who shared their expertise, the attendees who brought energy and great questions, and the supporters who brought this community together.
#DAVAHeadAndNeck
7
320
Dr. Jacob Thomas @uscnorris presents FID-007 plus cetuximab data in R/M HNSCC after prior immunotherapy, with a 61.9% ORR among 42 efficacy-evaluable patients and median PFS of 6.7 months in the 46-patient ITT population. #DAVAHeadAndNeck
Dr. @sueyom @UCSFcancer presents a 40-patient, double-blind, randomized phase III trial comparing miraculin with placebo for taste dysfunction during head and neck RT, assessing the impact of taste changes on dietary intake at week 3. #DAVAHeadAndNeck
Low-dose RT for polymetastaticdisease: Dr. @JJCaudell @MoffittNews outlines LIMETLESS, a single-arm phase I trial planned for 36 patients with >10 and up to 50 lesions, assessing technical feasibility of multisite online adaptive RT. #DAVAHeadAndNeck
Starting next: Local Therapies and Supportive Care
Moderator: Dr. @jdschoenfeld1 @DanaFarber
The session covers localized cisplatin, low-dose radiation to enhance immunotherapy, toxicity mitigation, cisplatin-related hearing effects and systemic combinations in HNSCC. #DAVAHeadAndNeck
Dr. Khaled Sanber @MDAndersonNews presents KSQ-004EX, SOCS1/Regnase-1-edited TILs with planned 20-patient expansion cohorts in six solid-tumor indications, including HNSCC, plus a 6-10-patient pembrolizumab combination cohort. #DAVAHeadAndNeck
Enhancing TIL therapy in head and neck cancer: @rbryanbell @ProvHealth reviews tumor-reactive cell selection, IL-2 support and early AGX-148 clinical findings, alongside strategies to overcome the suppressive tumor microenvironment. #DAVAHeadAndNeck
Dr. Deborah Wong @UCLAHealthJCCC presents early DENALI-1 results for A2B395, a logic-gated allogeneic EGFR-directed CAR-T therapy: CR in anal cancer and PR in head and neck cancer, with no DLTs or GVHD observed to date. #DAVAHeadAndNeck
Starting next: Cellular Therapies in Head and Neck Cancers
Moderator: Dr. Eric Sherman @MSKCancerCenter
The session will cover EGFR-directed CAR-T-cell therapy, strategies to enhance TIL activity and emerging engineered TIL approaches in head and neck cancers. #DAVAHeadAndNeck
Beyond PFS, SN2426/NRG-HN13 will assess RECIST 1.1 response, response duration, overall survival and toxicity. Dr. Paul Swiecicki @UMRogelCancer outlines analyses by cause of immunosuppression in recurrent inoperable or metastatic cutaneous SCC. #DAVAHeadAndNeck
Sinonasal cancer care depends on histology, molecular targets and resectability. Dr. Saad Khan @StanfordCancer reviews surgery and neoadjuvant therapy, including approaches to preserve orbital and skull-base structures. #DAVAHeadAndNeck
First-line toripalimab in R/M NPC: @sueyom @UCSFcancer reviews JUPITER-02, where adding toripalimab to gemcitabine/cisplatin improved median PFS to 21.4 vs 8.2 months (HR 0.52). Long-term median OS was 64.8 vs 33.7 months. #DAVAHeadAndNeck
Starting soon: Nasopharyngeal and Other Uncommon Cancers
Moderator: Dr. Paul Swiecicki @UMRogelCancer
Topics include toripalimab, sinonasal cancer care, NTRK3 in secretory cancers, amivantamab vs cetuximab and ANK-101 in cutaneous SCC. #DAVAHeadAndNeck






















































